Second-Line Immunotherapy Treatment Patterns In Non-Small Cell Lung Cancer In Portugal: An I-O Optimise Cohort Study

M. Soares,L. Antunes, J. Oliveira-Gomes, G. Pauperio,J. Cardia,P. Redondo,M. Borges, C. Chaib, L. Lacoin, F. Grimson, E. Ralphs,R. Munro, M. Daumont, J. R. Penrod, J. C. O'Donnell,M. J. Bento,F. Rocha Goncalves

Journal of Thoracic Oncology（2021）

引用 0|浏览5

暂无评分

摘要

In Portugal, the first immune checkpoint inhibitor (ICI) has been reimbursed since Feb 2017 for second-line (2L) treatment in patients with advanced non-small cell lung cancer (NSCLC). As part of I-O Optimise, a multinational research program on lung cancers utilizing real-world data, we describe early changes in 2L treatment patterns following the introduction of ICIs.

查看译文

关键词

Real-world data, Immune checkpoint inhibitor, observational cohort study

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要